Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, CA Cancer J Clin 2002;55:74–108.
   Google Scholar
• Ytting H, Jensenius JC, Thiel S, Jensenius JC, Nielsen HJ. Serum MASP-2 in colorectal cancer: relation to recurrence and mortality. Clin Cancer Res 2005;11:1441–6.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Verma M, Henson DE. Biomarkers for early detection of colon cancer. Clin Cancer Res 2001;7:1118–26.
   PubMed Web of Science ®Google Scholar
• Provenzale D, Gray RN. Colorectal cancer screening and treatment: review of outcomes research. J Natl Cancer Inst Monogr 2004;33:45–55.
   Google Scholar
• Ransohoff D. Colon cancer screening in 2005: Status and challenges. Gastroenterology 2005;128:1685–95.
   PubMed Web of Science ®Google Scholar
• Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467–71.
   PubMed Web of Science ®Google Scholar
• Hardcastle JD, Chamberlain JO, Robinson MH, Moss MC, Amar S, Balfour TW, Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472–7.
   PubMed Web of Science ®Google Scholar
• Kronborg O, Jørgensen OD, Fenger C, Rasmussen M. Randomised study of biennal screening with faecal occult blood test: results after nine screening rounds. Scand J Gastroenterol 2004;39:846–51.
   PubMed Web of Science ®Google Scholar
• Heresbach D, Manfredi S, D'halluin PN, Bretagne JF, Branger B. Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test. Eur J Gastroenterol Hepatol 2006;18:427–33.
   PubMed Web of Science ®Google Scholar
• Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg 2008;95:1029–36.
   PubMed Web of Science ®Google Scholar
• Young GP, St John JB, Winawer SJ, Rozen P. Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies. Am J Gastroenterol 2002;97:2499–507.
   PubMed Web of Science ®Google Scholar
• Nadel MR, Shapiro JA, Klabunde CN, Seeff LC, Uhler R, Smith RA, A national survey of primary care physicians' methods for screening for fecal occult blood. Ann Intern Med 2005;142:86–94.
   PubMed Web of Science ®Google Scholar
• Stokamer CL, Tenner CT, Chaudhuri J, Vazguez E, Bini EJ. Randomized controlled trial of the impact of intensive patient education on compliance with fecal occult blood testing. J Gen Intern Med 2005;20:278–82.
   PubMedGoogle Scholar
• Ransohoff DF. Rules of evidence for cancer molecular marker discovery and validation. Nat Rev 2004;4:309–14.
   Google Scholar
• Quyang DL, Chen JJ, Getzenberg RH. Noninvasive testing for colorectal cancer: a review. Am J Gastroenterol 2005;100:1393–403.
   PubMedGoogle Scholar
• Collins JF, Lieberman DA, Durbin TE, Weiss DG. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med 2005;142:81–5.
   PubMed Web of Science ®Google Scholar
• Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2007;16:1935–53.
   PubMed Web of Science ®Google Scholar
• Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny M, Macdonald JS, ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313–27.
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Høyer-Hansen G, Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999;80:495–503.
   PubMed Web of Science ®Google Scholar
• Sorensen NM, Sorensen IV, Würtz SØ, Schrohl AS, Dowell B, Davis G, Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment. Scand J Gastroenterol 2008;43:774–86.
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 2002;8:156–64.
   PubMed Web of Science ®Google Scholar
• Waas ET, Hendriks T, Lomme RM, Wobbes T. Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum 2005;48:700–10.
   PubMed Web of Science ®Google Scholar
• Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup JM, Tumor marker utility grading system: a framework to evaluate clinical utility of tumors markers. J Natl Cancer Inst 1996;88:1456–66.
   PubMed Web of Science ®Google Scholar
• Schrohl AS, Würtz S, Kohn E, Banks RE, Nielsen HJ, Sweep F, Banking of biological fluids for studies of protein biomarkers. Mol Cell Proteomics 2008;7:2061–6.
   PubMed Web of Science ®Google Scholar
• Nielsen HJ, Brünner N, Frederiksen C, Lomholt AF, King D, Jørgensen LN, Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): a novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian endoscopy study group on colorectal cancer detection. Scand J Gastroenterol 2008;43:242–8.
   PubMed Web of Science ®Google Scholar
• Davis GJ, Chan SS, Biegalski TT, Chan D, Dowell B. Analytical performance of an automated immunoassay for tissue inhibitor of metalloproteinases-1 (TIMP-1). J Clin Ligand Assays 2007;30:70–6.
   Google Scholar
• McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor Marker prognostic studies (REMARK). Breast Cancer Res Treat 2006;100:229–35.
   PubMed Web of Science ®Google Scholar
• Chan S, Biegalski T, Chan D, Dowell B, Davis GJ. Performance evaluation of a research use automated immunoassay for tissue inhibitor of metalloproteinases-1 (TIMP-1). Proc Clin Ligand Assay Soc (CLAS) 2007;40(Suppl.1):66.
   Google Scholar
• Hubl W, Zogbaum M, Boyd JC, Savory J, Schubert M, Meyer D, Evaluation of analytical methods and workflow performance of the Architect ci8200 integrated serum/plasma analyzer system. Clin Chim Acta 2005;357:43–54.
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Schrohl AS, Brünner N, Nielsen HJ, Høgdall CK, Høgdall EV. Evaluation of sample handling in relation to levels of tissue inhibitor of metalloproteinases-1 measured in blood by immunoassay. Int J Biol Markers 2003;18:170–6.
   PubMed Web of Science ®Google Scholar
• Lomholt AF, Frederiksen CB, Christensen IJ, Brünner N, Nielsen HJ. Plasma tissue inhibitor of metalloproteinases-1 as a biological marker? Preanalytical considerations. Clin Chim Acta 2007;380:128–32.
   PubMed Web of Science ®Google Scholar
• Frederiksen CB, Lomholt AF, Lottenburger T, Davis G, Dowell B, Blankenstein MA, Assessment of the biological variation of plasma tissue inhibitor of metalloproteinases-1. Int J Biol Markers 2007;23:42–7.
   Google Scholar
• Rouy D, Emens I, Jeanty C, Wagner DR. Plasma storage at –80°C does not protect matrix metalloproteinases-9 from degradation. Anal Biochem 2005;338:294–8.
   PubMed Web of Science ®Google Scholar
• Dresse M, Nagel D, Ganser EM, Davis G, Dowell B, Doss R, Dependence of TIMP-1 plasma levels on preanalytical specimen handling. Tumour Biol 2008;29:35–40.
   PubMedGoogle Scholar
• Maxwell PR, Timms PM, Chandran S, Gordon D. Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type-1 diabetes. Diabet Med 2001;18:777–80.
   PubMed Web of Science ®Google Scholar
• Lee SW, Song KE, Shin DS, Ahn SM, Ha ES, Kim DJ, Alterations in peripheral blood levels of TIMP-1, MMP-2 and MMP-9 in patients with type-2 diabetes. Diabetes Res Clin Pract 2005;69:175–9.
   PubMed Web of Science ®Google Scholar
• Flisiak R, Maxwell P, Prokopowicz D, Timms PM, Panasiuk A. Plasma tissue inhibitor of metalloproteinases-1 and transforming growth factor beta 1 – possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis. Hepatogastroenterology 2002;49:1369–72.
   PubMedGoogle Scholar
• Cavusoglu E, Ruwende C, Chopra V. Tissue inhibitor of metalloproteinase-s (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality and myocardial infarction. Am Heart J 2001;151:1101–8.
   Google Scholar
• Flisiak I, Porebski P, Chodynicka B. Effect of psoriasis activity on metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in plasma and lesional scales. Acta Derm Venerol 2006;86:17–21.
   PubMedGoogle Scholar
• Holten-Andersen MN, Stephens RW, Nielsen HJ, Murhpy G, Christensen IJ, Stetler-Stevenson W, High preoperative plasma TIMP-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 2000;6:4292–9.
   PubMed Web of Science ®Google Scholar
• Grützmann R, Molnar B, Pilarsky C, Habermann JK, Schlag PM, Saeger HD, Sensitive detection of colorectal cancer in peripheral blood by Septin 9 DNA methylation assay. PloS ONE 2008;3:1–8.
   Google Scholar
• deVos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J, Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 2009;55:1337–46.
   PubMed Web of Science ®Google Scholar
• Hammer JH, Basse L, Werther K, Svendsen NM, Brünner N, Christensen IJ, Impact of elective resection on plasma TIMP-1 levels in patients with colorectal cancer. Colorectal Dis 2006;8:168–72.
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Nielsen HJ, Sørensen S, Jensen V, Brünner N, Christensen IJ. Elevated postoperative plasma levels of tissue inhibitor of metalloproteinases-1 predict minimal residual disease in patients with colorectal cancer. Eur J Cancer 2006;42:1889–96.
   PubMed Web of Science ®Google Scholar
• Sørensen NM, Byström P, Christensen IJ, Berglund Å, Nielsen HJ, Brünner N, Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1) predicts objective response and survival in patients with metastatic colorectal cancer receiving first line treatment with irinotecan in combination with 5FU and Folinic acid. Clin Cancer Res 2007;13:4117–22.
   PubMed Web of Science ®Google Scholar